SL-1-39 [1-(4-chloro-3-methylphenyl)-3-(4-nitrophenyl)thiourea] is a new flexible heteroarotinoid (Flex-Het) analog derived from the parental compound, SHetA2, previously shown to inhibit cell growth across multiple cancer types. The current study aims to determine growth inhibitory effects of SL-1-39 across the different subtypes of breast cancer cells and delineate its molecular mechanism. Our results demonstrate that while SL-1-39 blocks cell proliferation of all breast cancer subtypes tested, it has the highest efficacy against HER2+ breast cancer cells. Molecular analyses suggest that SL-1-39 prevents S phase progression of HER2+ breast cancer cells (SKBR3 and MDA-MB-453), which is consistent with reduced expression of key cell-cycle r...
In the US breast cancer is the most common cancer after skin cancer. Currently in the US the average...
HER2 (human epidermal growth factor receptor-2) and/or estrogen receptor (ER) are overexpressed in ~...
Objectives Human epidermal growth factor receptor type 2 (HER2)-expressing breast cancer patients i...
SL-1-39 [1-(4-chloro-3-methylphenyl)-3-(4-nitrophenyl)thiourea] is a new flexible heteroarotinoid (F...
Breast cancer is the most common malignancy that occurs in women in the US and has the second highes...
The Human Epidermal growth factor Receptor-2 (HER2) involved in cancer signaling is a clinically val...
Potential chemopreventive and therapeutic value of the lead Flexible Heteroarotinoid (Flex-Het), SHe...
Breast cancer is one of the most lethal types of cancer in women worldwide due to the late stage det...
Introduction: Overexpression of the receptor tyrosine kinase HER2 has been reported in around 25% of...
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma ...
Field of study: Biomedical sciences.Dr. Salman M. Hyder, Dissertation Supervisor.Includes vita."May ...
Trastuzumab (Herceptin™) targets the human epidermal growth factor receptor 2 (HER2), which is overe...
Introduction: Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinom...
peer reviewedCancer prevention has a profound impact on cancer-associated mortality and morbidity. W...
Research performed over the last decade has highlighted the role of HDAC inhibitors (HDACis) as modu...
In the US breast cancer is the most common cancer after skin cancer. Currently in the US the average...
HER2 (human epidermal growth factor receptor-2) and/or estrogen receptor (ER) are overexpressed in ~...
Objectives Human epidermal growth factor receptor type 2 (HER2)-expressing breast cancer patients i...
SL-1-39 [1-(4-chloro-3-methylphenyl)-3-(4-nitrophenyl)thiourea] is a new flexible heteroarotinoid (F...
Breast cancer is the most common malignancy that occurs in women in the US and has the second highes...
The Human Epidermal growth factor Receptor-2 (HER2) involved in cancer signaling is a clinically val...
Potential chemopreventive and therapeutic value of the lead Flexible Heteroarotinoid (Flex-Het), SHe...
Breast cancer is one of the most lethal types of cancer in women worldwide due to the late stage det...
Introduction: Overexpression of the receptor tyrosine kinase HER2 has been reported in around 25% of...
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma ...
Field of study: Biomedical sciences.Dr. Salman M. Hyder, Dissertation Supervisor.Includes vita."May ...
Trastuzumab (Herceptin™) targets the human epidermal growth factor receptor 2 (HER2), which is overe...
Introduction: Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinom...
peer reviewedCancer prevention has a profound impact on cancer-associated mortality and morbidity. W...
Research performed over the last decade has highlighted the role of HDAC inhibitors (HDACis) as modu...
In the US breast cancer is the most common cancer after skin cancer. Currently in the US the average...
HER2 (human epidermal growth factor receptor-2) and/or estrogen receptor (ER) are overexpressed in ~...
Objectives Human epidermal growth factor receptor type 2 (HER2)-expressing breast cancer patients i...